Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

- Research collaboration for new therapeutic peptides
- Ipsen to have an option to exclusive rights to develop and commercialize new drug candidates

Paris (France) and Osaka-City (Japan), 19 November 2015 - Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty driven pharmaceutical Group, and Interprotein Corporation (Interprotein), a Japanese R&D focused biotechnology company, today announced that they have signed a research collaboration and an option agreement to develop and commercialize new therapeutic peptides intended for serious medical conditions in endocrinology, such as Cushing’s disease.

Under the terms of the agreement, Ipsen will combine its expertise in design and development of therapeutic peptides targeting specific receptors with Interprotein’s Protein-Protein Interaction (PPI) and helix-loop-helix-peptide (HLHP) technologies.

“We are very excited to be involved in Ipsen’s innovative drug discovery program for this rare disease. We are particularly proud that our technological platform has been selected to advance Ipsen’s target molecules. This agreement fits our strategy to partner on PPI targeted Drug Discovery activities“, said Masato Hosoda, Chief Executive Officer at Interprotein. “Our intention is for this partnership between Ipsen and Interprotein to potentially provide an innovative solution to improve quality of life of patients with serious diseases, and consequently reinforce the value of HLHP as therapeutic PPI inhibitors“, said Hirotsgu Komatsu, Ph.D., Chief Scientific Officer at Interprotein.

Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen stated: “Ipsen looks forward to benefiting from Interprotein’s innovative peptide discovery technologies to support Ipsen’s leading therapeutic peptide R&D capabilities and to developing new therapeutic solutions for serious unmet medical needs. Such a collaboration exemplifies Ipsen’s strategy in R&D where open innovation and partnerships are key to advance treatments in its focused medical areas.”
Under the financial terms of the agreement, should Ipsen exercise its option and fully develop the compound(s), payments to Interprotein could reach up to €165 million, in upfront, success-driven R&D, regulatory and commercial milestones, with additional royalties on world-wide annual net sales.

About Interprotein

Interprotein is focusing on PPIs as drug targets with great potential and conducting drug discovery research of PPI antagonists and agonists using two technology platforms, i.e. helix-loop-helix peptides (HLHP) and INTerprotein’s Engine for New Drug Design (INTENDD®). HLHP is a conformationally-constrained peptide with two helices linked on both sides, and INTENDD® is a strategic approach for structure-based drug discovery (SBDD) of small molecules and can efficiently identify new drug-like scaffolds by Structure-Based Scaffold Generation (SGSG®) method. For additional information, please visit http://www.interprotein.com.

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Ipsen Forward Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

For further information:

**Ipsen**

**Media**

Didier Véron  
Senior Vice-President, Public Affairs and Communication  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: didier.veron@ipsen.com

**Brigitte Le Guennec**  
Corporate External Communication  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail: brigitte.le.guennec@ipsen.com

**Financial Community**

Stéphane Durant des Aulnois  
Vice-President, Investor Relations  
Tel.: +33 (0)1 58 33 60 09  
Fax: +33 (0)1 58 33 50 63  
E-mail: stephane.durant.des.aulnois@ipsen.com

Côme de La Tour du Pin  
Investor Relations Manager  
Tel.: +33 (0)1 58 33 53 31  
Fax: +33 (0)1 58 33 50 63  
E-mail: come.de.la.tour.du.pin@ipsen.com

**Interprotein**

Hirot sugu Komatsu, Ph.D.  
CSO and Director, R&D and BD Division  
TEL.: +81-(0)42-770-9477  
FAX: +81-(0)42-770-9477  
E-mail: komatsu@interprotein.com